Search


PDF Archive search engine
Last database update: 17 July at 11:24 - Around 76000 files indexed.


Show results per page

Results for «immunotherapy»:


Total: 36 results - 0.019 seconds

ER1234 100%

2ND r INTERNATIONAL NTNU SYMPOS UM 5 CURRENT AND FUTURE CLINICAL BIOMARKERS OF CANCER NTE i RNR T I ON H NTNU L SYMPOSIUMON i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i C L(N I Cfi L B l0M RRKERSO FCANCER From diagnosis to immunotherapy - why is precision medicine so difficult?

https://www.pdf-archive.com/2019/06/11/er1234/

11/06/2019 www.pdf-archive.com

Document-2 93%

Results with a new type of treatment--oral immunotherapy--may reduce the risk of developing anaphylaxis by slowly training the immune system not to react to peanut ingestion by triggering a potentially fatal allergic reaction.

https://www.pdf-archive.com/2014/02/03/document-2/

03/02/2014 www.pdf-archive.com

ER1235 91%

ESMO ADVANCED COURSE PROGRAMME LUNG CANCER IN IMMUNOTHERAPY A NEW PARADIGM WITH UNANSWERED QUESTIONS Zurich, Switzerland 3-4 July 2019 CO-CHAIRS Aurelien Marabelle, France SPEAKERS John Haanen, Netherlands Maurice Perol, France Solange Peters, Switzerland David Planchard, France LEARNING OBJECTIVES Understanding the key players in tumour immunology Getting up-to-date on the role of immunotherapy in advanced NSCLC The role of biomarkers in selecting NSCLC patients for IT Mechanism of combining angiogenesis inhibition with checkpoint inhibition Management of IT toxicity and use of IT in specific subgroups of patients ACCREDITATION The programme of this event has been accredited with 10 ESMO-MORA category 1 points.

https://www.pdf-archive.com/2019/06/11/er1235/

11/06/2019 www.pdf-archive.com

ER1085 89%

Maurice Perol 15h30 | COFFEE BREAK 15h45 | IMMUNOTHERAPY:

https://www.pdf-archive.com/2018/08/13/er1085/

13/08/2018 www.pdf-archive.com

Official Event Guide ICI Europe 06.11.18 87%

Head of Immunotherapy Lab VU University Medical Center Programme Partners Tel:

https://www.pdf-archive.com/2018/11/12/officialeventguideicieurope061118/

12/11/2018 www.pdf-archive.com

lsc-htbx-note-02022016 84%

HTBX) presented 3 month interim data from an open-label arm of a Phase II trial with immunotherapy candidate HS-410 in patients with non-muscle invasive bladder cancer (NMIBC).

https://www.pdf-archive.com/2016/08/11/lsc-htbx-note-02022016/

11/08/2016 www.pdf-archive.com

32nd Consensus Conference 81%

Molecular Tumor Board 14:10-14:20 10min Q&A Immunotherapy for Colorectal Cancer 좌장 :

https://www.pdf-archive.com/2018/04/06/32nd-consensus-conference/

06/04/2018 www.pdf-archive.com

27th Consensus Conference 79%

아울러 세번째 세션에서는 최근 화두가 되고 있는 Immunotherapy에 대 해 임상의사를 위한 이론과 실제를 준비해 보았습니다.

https://www.pdf-archive.com/2018/04/06/27th-consensus-conference/

06/04/2018 www.pdf-archive.com

May June 2017 (1) 77%

27 20 26 there is community here WEEKLY SUPPORT GROUPS IMMUNOTHERAPY YOGA PEER DISCUSSION GROUPS PATIENT GROUP:

https://www.pdf-archive.com/2017/04/24/may-june-2017-1/

24/04/2017 www.pdf-archive.com

2826 Pathology Meeting program 69%

Mark Routbort, The University of Texas MD Anderson Cancer Center, Houston, USA Predictive biomarkers for lung cancer immunotherapy Dr.

https://www.pdf-archive.com/2018/08/08/2826pathology-meetingprogram/

08/08/2018 www.pdf-archive.com

31st Consensus Conference 67%

2 면 10:30-10:40 러들로 교수동 연세암병원 방 10min 회원 이대역 포 10:20-10:30 정민규(연세의대) 마 Patient selection and combination strategy of immunotherapy 재활병원 제중관 <

https://www.pdf-archive.com/2018/04/06/31st-consensus-conference/

06/04/2018 www.pdf-archive.com

Program Annual Meeting 2017 v6.5 63%

Innovation in Immunotherapy Clinical Trials Aurélien Marabelle (GR) Dirk Jäger (DKFZ) Short talk - Alena Gros (VHIO) Discussion Thomas Hudson - AbbVie 02:50 - 4:00 PM 02:50 03:05 03:20 03:35 3:45 - 4:00 PM 4 - 4:15 PM SESSION 5:

https://www.pdf-archive.com/2016/12/07/program-annual-meeting-2017-v6-5/

07/12/2016 www.pdf-archive.com

ER1143 60%

Ian Jenkins Elizabeth Smyth Immunotherapy for rectal cancer:

https://www.pdf-archive.com/2018/11/30/er1143/

30/11/2018 www.pdf-archive.com

CCE Meeting Program v7 58%

Innovation in Immunotherapy Clinical Trials Sandrine Aspeslagh (GR) TBC Dirk Jäger (DKFZ) Understanding response and resistance as endpoints of clinical trials Short talk - Alena Gros (VHIO) Neoantigen specific lymphocytes in liquid biopsies Discussion Thomas Hudson - AbbVie TBC Christophe Massard (GR) Simon Ekman (KI) Irene Braña (VHIO) Short talk - Yohann Loriot (GR) SESSION 5:

https://www.pdf-archive.com/2016/12/22/cce-meeting-program-v7/

22/12/2016 www.pdf-archive.com

ER1225 1 57%

hurdles and opportunities Monique den Boer (Utrecht) 10:35-10:50 The changing pattern of relapse in the immunotherapy era Andre Baruchel (Paris) 10:50-11:05 Discussion 5 SESSION VII - T-CELL ALL/LL Chair:

https://www.pdf-archive.com/2019/05/07/er12251/

07/05/2019 www.pdf-archive.com

ER1225 56%

10:00-10:30 Coffee break SESSION IV - IMMUNOTHERAPY FOR ALL Chair:

https://www.pdf-archive.com/2019/05/07/er1225/

07/05/2019 www.pdf-archive.com

2017DBS Antibody Flyer 102017 web 56%

Thus, MammaglobinA-specific T Cell immune responses may provide an important approach for the design of breast cancerspecific immunotherapy.

https://www.pdf-archive.com/2017/10/30/2017dbs-antibody-flyer-102017-web/

30/10/2017 www.pdf-archive.com

310812900-Final-Announcement-ROICAM-4 55%

Immunotherapy on Cancer Management, problems in health service on The National Health Insurance (JKN) era, Bone Marrow Transplantation, Stem Cells, also advancement in cancer supportive treatment, such as blood component transfusion, anemia, thrombosis, cancer pain, and updates on systemic therapy, including newest medications on the treatment of most frequent cancers;

https://www.pdf-archive.com/2018/02/19/310812900-final-announcement-roicam-4/

19/02/2018 www.pdf-archive.com

The Blood, The Marrow, The Giant Needle 55%

We have bee using stop-gap measures like transfusions, immunotherapy, steroids, animal sacrifice, etc.

https://www.pdf-archive.com/2016/04/24/the-blood-the-marrow-the-giant-needle/

24/04/2016 www.pdf-archive.com

sept 3 54%

The therapy is a genetically-modified autologous T-cell immunotherapy.

https://www.pdf-archive.com/2017/09/14/sept-3/

14/09/2017 www.pdf-archive.com

Models paper final 26 Apr 54%

Referral to a specialist with expertise in allergy is required for anaphylaxis and severe forms of drug, food, latex and venom allergy and immunotherapy and multi-system allergic disease.

https://www.pdf-archive.com/2012/04/23/models-paper-final-26-apr/

23/04/2012 www.pdf-archive.com

ESMO-Preceptorship-on-Lung-Cancer-Manchester-2020-Programme.ocr 53%

Enriqueta Felip, ES Raffaele Califano, UK Neil Bayman, UK 30’ Prophylactic cranial irradiation and role of thoracic RT for extensive stage SCLC 30’ Cellular immunotherapy Fiona Thistlethwaite, UK Conclusion and farewell Raffaele Califano, UK 16:15-16:20 5’

https://www.pdf-archive.com/2020/01/17/esmo-preceptorship-on-lung-cancer-manchester-2020-programmeocr/

17/01/2020 www.pdf-archive.com

ASH 2011 Bystander vaccine poster 52%

Wilm’s Tumor protein 1 (WT1) and Cancer Testis Antigens (CTAs) are solid candidates for future immunotherapy and vaccines containing these antigens are currently under development in solid and hematological malignancies.

https://www.pdf-archive.com/2011/12/08/ash-2011-bystander-vaccine-poster/

08/12/2011 www.pdf-archive.com

BTOG-2019-Programme-V7-Draft 48%

will immunotherapy cure lung cancer?

https://www.pdf-archive.com/2018/12/10/btog-2019-programme-v7-draft/

10/12/2018 www.pdf-archive.com